FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The Blacklisting of Peptides FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA considers adding a dozen peptides to its bulk drug compounding list RAPS Check out FDAs new roster of bulk drug substances being pulled from use in compounding. Youll see BPC 157 and TB 500 among the various peptides added to the list of category 2 substances Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #